794518-57-3 Usage
Description
(R)-methyl 2-(benzylamino)-3-((tert-butyldimethylsilyl)oxy)propanoate is a chemical compound that belongs to the class of organosilicon compounds. It is a derivative of propanoate, with a benzylamino group and a tert-butyldimethylsilyl group attached to the third carbon. This chiral compound, with a specific orientation around the carbon atom, has potential applications in organic synthesis and medical research due to its unique structure and properties. Its interesting chemical and biological properties make it valuable for various scientific and industrial applications.
Uses
Used in Organic Synthesis:
(R)-methyl 2-(benzylamino)-3-((tert-butyldimethylsilyl)oxy)propanoate is used as an intermediate in the synthesis of various organic compounds for [application reason] its unique structure and properties that facilitate specific chemical reactions and transformations.
Used in Medical Research:
In the field of medical research, (R)-methyl 2-(benzylamino)-3-((tert-butyldimethylsilyl)oxy)propanoate is used as a chiral building block for [application reason] its importance in asymmetric synthesis and drug development, which can lead to the creation of new pharmaceuticals with improved efficacy and selectivity.
Used in Pharmaceutical Industry:
(R)-methyl 2-(benzylamino)-3-((tert-butyldimethylsilyl)oxy)propanoate is used as a key component in the development of new drugs for [application reason] its potential to be incorporated into the molecular structure of pharmaceuticals, enhancing their therapeutic properties and targeting specific biological pathways.
Used in Chemical Research:
In the chemical research industry, (R)-methyl 2-(benzylamino)-3-((tert-butyldimethylsilyl)oxy)propanoate is used as a model compound for [application reason] studying the effects of its unique structural features on chemical reactivity and understanding the underlying mechanisms of various reactions.
Check Digit Verification of cas no
The CAS Registry Mumber 794518-57-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,9,4,5,1 and 8 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 794518-57:
(8*7)+(7*9)+(6*4)+(5*5)+(4*1)+(3*8)+(2*5)+(1*7)=213
213 % 10 = 3
So 794518-57-3 is a valid CAS Registry Number.
794518-57-3Relevant articles and documents
HIV PROTEASE INHIBITORS
-
, (2015/07/07)
The present invention is directed to 5-heteroarylmorpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Novel approach to the (-)-sparteine-mediated synthesis of kainoids: Total synthesis of (-)-α-kainic acid by (-)-sparteine-mediated deprotonation
Martinez, M. Montserrat,Hoppe, Dieter
, p. 1427 - 1443 (2007/10/03)
We report a new synthesis of kainoids via allyllithium compounds using an intramolecular cycloalkylation as the key step. Preparation of different substituted pyrrolidines was carried out by using carbamates, that react with the chiral base n-BuLi/(-)-sparteine with strong selection between the diastereotopic protons adjacent to the carbamate group in favour for the pro-S proton. (-)-α-Kainic acid was synthetized from D-serine methyl ester hydrochloride, based on a (-)-sparteine-mediated asymmetric deprotonation of an intermediate carbamate that, by stereospecific anti-SN′S E′ intramolecular cycloalkylation, leads to the pyrrolidine ring precursor of (-)-α-kainic acid, in high yield and diastereoselectivity. Related approaches, starting from L-glutamic acid failed. The intermediate pyrrolidine was further transformed to (-)-α-kainic in three steps. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005.
